Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement With the Medtronic Spinal Division
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement With the Medtronic Spinal Division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries
Kuros will work collaboratively to sell, market and provide support services to Medtronic's sales force
Kuros will keep responsibility for contracts, hospital partnerships and the recognition of revenue from sales
Kuros will continue to sell directly in non-contracted territories as well as in markets outside of spine
This agreement transforms an initial trial agreement into a strategic alliance
美敦力將作爲Kuros Biosciences USA, Inc.在雙方商定的銷售區域內的MagnetsTm獨家銷售代理，用於脊柱手術。
Kuros將與美敦力的銷售團隊合作銷售、營銷並提供支持服務。
Kuros將繼續負責合同、醫院夥伴關係以及銷售營收的確認。
Kuros將在非合同區域以及脊柱以外的市場繼續直接銷售。
這項協議將初步的試用協議轉變爲戰略聯盟。
SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 7, 2025 / Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with Medtronic, a leading global healthcare technology company. The agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros' pioneering MagnetOs bone grafting technology.
瑞士施利倫 / ACCESSWIRE / 2025年1月7日 / Kuros Biosciences USA Inc.（"Kuros"），Kuros Biosciences AG的全資子公司，全球領先的愛文思控股骨癒合技術公司，今天宣佈與美敦力簽署一項爲期五年的戰略獨家銷售代理協議。該協議爲美敦力在美國市場某些脊柱地區提供了獨佔性，強調了雙方擴大Kuros開創性的MagnetOs骨移植技術獲取機會的共同承諾。
This agreement positions Kuros for new opportunities in the U.S. spine market and also paves the way for broader adoption of the MagnetOs family of products, which are supported by robust clinical data and innovative designs. This agreement transforms an initial trial agreement into a strategic alliance for a period of five years.
該協議爲Kuros在美國脊柱市場提供了新機會，並且爲MagnetOs系列產品的更廣泛採用鋪平了道路，這些產品得到了強有力的臨牀數據和創新設計的支持。該協議將初步的試用協議轉變爲爲期五年的戰略聯盟。
Chris Fair, Chief Executive Officer of Kuros Biosciences, commented: "What started as a trial agreement has now evolved into a strategic alliance with Medtronic reflecting an important milestone for Kuros. This agreement will also help us drive the scaling up process, further optimize our operating leverage, and continue our rapid revenue growth both with Medtronic and in our own direct channels."
Kuros Biosciences首席執行官Chris Fair評論道："最初的試用協議如今已經演變爲與美敦力的戰略聯盟，這對Kuros來說是一個重要的里程碑。該協議還將幫助我們推動規模化進程，進一步優化我們的運營槓桿，並繼續我們的營業收入快速增長，無論是在美敦力方面，還是在我們自己的直接渠道中。"
For further information, please contact:
如需更多信息，請聯繫：
Kuros Biosciences AG |
|
Kuros Biosciences AG |
|
About MagnetOs
MagnetOs is a bone graft like no other: thanks to its NeedleGripTM surface technology, it grows bone even in soft tissues. This surface technology provides traction for our body's vitally important 'pro-healing' immune cells (M2 macrophages). This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft. The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion.*†‡1-5
關於MagnetOs
MagnetOs是一種獨特的骨移植材料：得益於其 NeedleGripTm 表面技術，能夠在軟組織中生長出骨頭。這種表面技術爲我們身體至關重要的「促進癒合」免疫細胞（M2巨噬細胞）提供了牽引力。這反過來解鎖了以前未開發的潛力，能夠刺激幹細胞——並在整個移植物中形成新骨。關於 NeedleGrip 的不斷增長的科學研究被稱爲骨免疫學。但對於外科醫生和他們的病人來說，這意味着一件事：更可預測的融合。*†‡1-5
Indications statement
Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings and precautions.
適應症聲明
請參考您所在地區的使用說明書，以獲取適應症、禁忌症、警告和注意事項的完整列表。
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit kurosbio.com.
關於Kuros生物科學
Kuros生物科學的使命是發現、開發和交付創新的生物技術。公司在美國、瑞士和荷蘭設有辦事處，並在瑞士證券交易所上市。公司的第一個商業產品MagnetOsTm是一種獨特的先進骨移植材料，已經在四大洲使用。欲了解有關公司、其產品和產品線的更多信息，請訪問kurosbio.com。
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
前瞻性聲明
本媒體發佈包含某些前瞻性陳述，這些陳述涉及風險和不確定性，可能導致實際結果與歷史結果或任何未來結果存在重大差異，這些未來結果在此類前瞻性陳述中表示或暗示。我們建議您考慮包含「將」或「期望」以及這些詞的否定形式或其他類似詞的陳述，這些陳述是不確定和前瞻性的。可能導致實際結果與任何未來結果存在重大差異的因素包括科學、商業、經濟和財務因素。在這些不確定性背景下，讀者不應依賴前瞻性陳述。公司不承擔更新前瞻性陳述或將其調整至未來事件或發展的責任。
* Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
† MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
‡ MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
* 體內實驗室測試的結果可能無法預測人類的臨牀體驗。有關重要的安全性和預期使用信息，請訪問 kurosbio.com。
† MagnetOs 尚未獲得 FDA 或 TGA 的批准作爲骨誘導骨移植。
‡ MagnetOs 已被證明在一個羔羊的背外側融合模型中，比兩種商業可用的替代品生成更可預測的融合。
1. Van Dijk, et al. eCM. 2021; 41:756-73.
2. Duan, et al. eCM. 2019; 37:60-73.
3. Van Dijk, et al. Clin Spine Surg. 2020;33(6): E276-E287.
4. Van Dijk, et al. JOR Spine. 2018; e1039.
5. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
1. Van Dijk 等人，eCm. 2021; 41:756-73。
2. Duan 等人，eCm. 2019; 37:60-73。
3. Van Dijk 等人，Clin Spine Surg. 2020;33(6): E276-E287。
4. Van Dijk等。JOR脊柱。2018；e1039。
5. Van Dijk等。生物醫學材料研究。第B部分：應用生物材料。2019；107(6)：2080-2090。
SOURCE: Kuros Biosciences AG
來源：Kuros生物科學有限公司
